SLIDESHOW: Vitiligo Treatments Through Time

What do you think the most significant vitiligo treatments are? Do you have an interesting case to share? We would love to hear from you! Email DTEditor@mmhgroup.com.

References

1. Cunningham K, Rosmarin D. Vitiligo treatments: review of current therapeutic modalities and JAK inhibitors. Am J Clin Dermatol. 2023;24(2):165-186. doi:10.1007/s40257-022-00752-6
2. Dhanik A, Sujatha N, Rai N. Clinical evaluation of the efficacy of Shvitraharakashaya and lepa in vitiligo. Ayu. 2011;32(1):66-69. doi:10.4103/0974-8520.85731
3. Das A, Panda S. Use of topical corticosteroids in dermatology: an evidence-based approach. Indian J Dermatol. 2017;62(3):237-250. doi:10.4103/ijd.IJD_169_17
4. Bleehen SS. The treatment of vitiligo with topical corticosteroids. Light and electronmicroscopic studies. Br J Dermatol. 1976;94 suppl 12:43-50. doi:10.1111/j.1365-2133.1976.tb02268.x
5. Shenoi SD, Prabhu S. Photochemotherapy (PUVA) in psoriasis and vitiligo. Indian J Dermatol VenereolLeprol. 2014;80(6):497-504. doi:10.4103/0378-6323.144143
6. Myers E, Kheradmand S, Miller R. An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases. Cureus. 2021;13(11):e19182. Published 2021 Nov 1. doi:10.7759/cureus.19182
7. Lee JH, Kwon HS, Jung HM, et al. Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019;155(8):929–938. doi:10.1001/jamadermatol.2019.0696
8. Post NF, Ezekwe N, Narayan VS, et al. The use of lasers in vitiligo, an overview. J EurAcad Dermatol Venereol. 2022;36(6):779-789. doi:10.1111/jdv.18005
9. Toh J, Chuah S, Jhingan A, Chong W, Thng S. Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians. J Am Acad Dermatol. 2020;82(6):1517-1519. doi:10.1016/j.jaad.2020.01.035
10. Rosmarin D, Passeron T, Pandya AG, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022;387(16):1445-1455. doi:10.1056/NEJMoa2118828
11. New long-term data from Incyte phase 3 TRuE-V program demonstrates efficacy of continued treatment with Opzelura® (ruxolitinib) cream in nonsegmental vitiligo patients. News release. Incyte. October 11, 2023. Accessed June 25, 2024. https://investor.incyte.com/news-releases/news-release-details/new-long-term-data-incyte-phase-3-true-v-program-demonstrates